Stanislas Goriely
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stanislas Goriely has a total of 522 co-authors. Here are the top co-authors by number of shared publications:
- Abdulkader Azouz
Universite Libre de Bruxelles
33 shared publications - Muriel Moser
Laboratoire d’Immunobiologie, Université Libre de Bruxelles (ULB), Gosselies, Belgium
23 shared publications - Oberdan Leo
U-CRI (ULB Center for Research in Immunology), Université Libre de Bruxelles (ULB)
23 shared publications - Coralie Henin
Laboratoire d’Immunobiologie, Université Libre de Bruxelles (ULB), Gosselies, Belgium
21 shared publications - Sébastien Denanglaire
Laboratory of Immunobiology, Department of Molecular Biology, Faculty of Sciences, Université Libre de Bruxelles, Gosselies, Belgium
20 shared publications Fabienne Willems
Institute for Medical Immunology (IMI), Université Libre de Bruxelles, Charleroi, Belgium
18 shared publications
Latest Publications
- Open Access
- 13 February 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (2) , 116977
In vivo modeling of human γδ T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 Vδ2 T cell development
- 13 February 2026
- Published by Elsevier in Cell Reports
- Vol. 45 (2) , 116977
Open AccessIn vivo modeling of human γδ T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 Vδ2 T cell development
- Open Access
- 19 January 2026
- Published by Springer Nature in Research Square
Regulatory Networks Shaping Human Tumor-Associated Macrophages In Vivo Identify MAFB as a Key Transcriptional Driver
Tumor-associated macrophages (TAMs) are central drivers of resistance to conventional and immune-based therapies. Recent single-cell studies have uncovered an unexpected heterogeneity of macrophage states in human cancers, moving beyond the simplistic “M1–M2” paradigm. However, progress in understanding human TAM biology has been hampered by the lack of physiologically relevant in vivo models. Here, we leverage next-generation humanized mouse models implanted with cell line xenografts (CDX) to dissect the transcriptional and epigenetic programs that shape monocyte-to-macrophage differentiation within the tumor microenvironment. We show that these immuno-CDX models faithfully reproduce the phenotypic and molecular hallmarks of TAMs observed in patient tumors. By integrating single-cell transcriptomic and chromatin accessibility profiling with high-dimensional co-expression and enhancer-driven regulatory network analyses, we reconstruct a comprehensive framework of human TAM states. Furthermore, CRISPR-mediated gene editing of hematopoietic stem cells prior to humanization identifies MAFB as a key regulator of TAM plasticity. Our findings establish humanized models as a powerful platform to study TAM biology in vivo, uncover fundamental regulators of macrophage plasticity, and highlight new therapeutic targets for next-generation cancer immunotherapies.
- 19 January 2026
- Published by Springer Nature in Research Square
Open AccessRegulatory Networks Shaping Human Tumor-Associated Macrophages In Vivo Identify MAFB as a Key Transcriptional Driver
Tumor-associated macrophages (TAMs) are central drivers of resistance to conventional and immune-based therapies. Recent single-cell studies have uncovered an unexpected heterogeneity of macrophage states in human cancers, moving beyond the simplistic “M1–M2” paradigm. However, progress in understanding human TAM biology has been hampered by the lack of physiologically relevant in vivo models. Here, we leverage next-generation humanized mouse models implanted with cell line xenografts (CDX) to dissect the transcriptional and epigenetic programs that shape monocyte-to-macrophage differentiation within the tumor microenvironment. We show that these immuno-CDX models faithfully reproduce the phenotypic and molecular hallmarks of TAMs observed in patient tumors. By integrating single-cell transcriptomic and chromatin accessibility profiling with high-dimensional co-expression and enhancer-driven regulatory network analyses, we reconstruct a comprehensive framework of human TAM states. Furthermore, CRISPR-mediated gene editing of hematopoietic stem cells prior to humanization identifies MAFB as a key regulator of TAM plasticity. Our findings establish humanized models as a powerful platform to study TAM biology in vivo, uncover fundamental regulators of macrophage plasticity, and highlight new therapeutic targets for next-generation cancer immunotherapies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Identification of predominant IFNγ-producing cell population and their functional characterization
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Identification of predominant IFNγ-producing cell population and their functional characterization
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is associated with subsets exhibiting elevated expression of MHC II
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is associated with subsets exhibiting elevated expression of MHC II
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Although immune checkpoint inhibitors have led to durable responses in various cancer types, a substantial proportion of patients do not respond to these interventions. To uncover potential factors associated with a positive response to immunotherapy, we used a bilateral tumor model with P815 mastocytoma implanted in DBA/2 mice. In this model, only a fraction of tumor-bearing mice responds to anti–PD-1 treatment. Thus, it provides a valuable model to explore the influence of the tumor microenvironment (TME) in determining the efficacy of immune checkpoint blockade–based immunotherapies. It also allows for the analysis of a pretreatment tumor and inference of its treatment outcome based on the response observed in the contralateral tumor. In this study, we report that tumor-reactive CD8+ T-cell clones expressing high levels of Tim-3 are associated with a positive antitumor response following anti–PD-1 administration. Our study also revealed distinct differentiation dynamics in tumor-infiltrating myeloid cells in responding and nonresponding mice. An IFNγ-enriched TME promoted the differentiation of monocytes into PD-L1posMHCIIhigh cells in mice responding to immunotherapy. Monocytes present in the TME of nonresponding mice failed to reach the same final stage of differentiation trajectory, suggesting that an altered monocyte-to-macrophage differentiation route may hamper the response to immune checkpoint blockade. These insights will direct future research toward a temporal analysis of tumor-associated macrophages, aiming to identify factors responsible for transitions between differentiation states within the TME. This approach may pave the way for novel strategies to enhance the efficacy of PD-1 blockade.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Although immune checkpoint inhibitors have led to durable responses in various cancer types, a substantial proportion of patients do not respond to these interventions. To uncover potential factors associated with a positive response to immunotherapy, we used a bilateral tumor model with P815 mastocytoma implanted in DBA/2 mice. In this model, only a fraction of tumor-bearing mice responds to anti–PD-1 treatment. Thus, it provides a valuable model to explore the influence of the tumor microenvironment (TME) in determining the efficacy of immune checkpoint blockade–based immunotherapies. It also allows for the analysis of a pretreatment tumor and inference of its treatment outcome based on the response observed in the contralateral tumor. In this study, we report that tumor-reactive CD8+ T-cell clones expressing high levels of Tim-3 are associated with a positive antitumor response following anti–PD-1 administration. Our study also revealed distinct differentiation dynamics in tumor-infiltrating myeloid cells in responding and nonresponding mice. An IFNγ-enriched TME promoted the differentiation of monocytes into PD-L1posMHCIIhigh cells in mice responding to immunotherapy. Monocytes present in the TME of nonresponding mice failed to reach the same final stage of differentiation trajectory, suggesting that an altered monocyte-to-macrophage differentiation route may hamper the response to immune checkpoint blockade. These insights will direct future research toward a temporal analysis of tumor-associated macrophages, aiming to identify factors responsible for transitions between differentiation states within the TME. This approach may pave the way for novel strategies to enhance the efficacy of PD-1 blockade.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Effect of blocking IFNγ is particularly pronounced within myeloid cell populations
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Effect of blocking IFNγ is particularly pronounced within myeloid cell populations
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Flow cytometry gating strategy to analyze the influence of tumor-infiltrating immune cells on the response to immunotherapy
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Flow cytometry gating strategy to analyze the influence of tumor-infiltrating immune cells on the response to immunotherapy
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
P1A-specific CD8+ T cell infiltration is not sufficient alone for a successful tumor response
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
P1A-specific CD8+ T cell infiltration is not sufficient alone for a successful tumor response
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is linked to the M_3 scRNA-seq cluster
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Enhanced antigen-presenting capacity is linked to the M_3 scRNA-seq cluster
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Comparative analysis of myeloid immune infiltrate composition in bilateral tumors
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from IFNγ-Induced PD-L1+MHCII+ Macrophages and Tim-3+ Tumor-Reactive CD8+ T Cells Predict a Response to Anti–PD-1 Therapy in Tumor-Bearing Mice
Comparative analysis of myeloid immune infiltrate composition in bilateral tumors